Experimental CAR t therapy takes on Hard-to-Treat prostate cancer
NCT ID NCT07543055
First seen Jun 25, 2026 · Last updated Aug 11, 2026 · Updated 6 times
Summary
This early-stage study tests BPX-601, a personalized CAR T cell therapy made from a patient's own immune cells, for advanced prostate cancer that has spread and stopped responding to other treatments. The trial will enroll 36 people to find the safest dose and check for side effects, while also seeing if the therapy can shrink tumors or lower PSA levels. It is not yet recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BPX-601 (a CAR T cell therapy made from the patient's own immune cells)
- What this could lead to
- If successful, this could point toward a new treatment option for advanced prostate cancer that has stopped responding to standard therapies.
- What could go wrong
- This is an early Phase 1 trial with only 36 participants, so it is primarily testing safety and dosing. The treatment may not shrink tumors or could cause serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
John Theurer Cancer Center
RECRUITINGHackensack, New Jersey, 07601, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tracer light up hidden prostate cancer?
- Chemo combo vs. radioactive drug: which tames aggressive prostate cancer?
- Could deep breaths before surgery ward off Post-Op confusion?
- Can a new pill outsmart resistant prostate cancer?
- A second look: MRI screening may spot hidden prostate cancers
- Can a radioactive 'Smart Bomb' outsmart advanced prostate cancer?